CANY
WVE icon

Caxton Associates (New York)’s Wave Life Sciences WVE Stock Holding History

Caxton Associates (New York)’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,013
Closed -$87K – 631
2022
Q3 		$87K Buy
+24,013
New +$79.5K 0.01% 446

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caxton Associates (New York)'s WVE Position: Q4 2022 in Review

Caxton Associates (New York) sold out of Wave Life Sciences (WVE) in Q4 2022, closing a stake of 24,013 shares — an estimated $87K sold.

Caxton Associates (New York) first reported a position in WVE in Q3 2022 and held it in 1 quarter. The position peaked at $87K in Q3 2022. 75 funds tracked by Wall St. Rank hold WVE as of Q4 2022.

  • Caxton Associates (New York) reported no remaining Wave Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 24,013 Wave Life Sciences shares in Q4 2022, an estimated $87K.
  • Caxton Associates (New York) first reported a position in Wave Life Sciences in Q3 2022 and held it in 1 quarter.
  • Caxton Associates (New York)'s Wave Life Sciences position peaked at $87K in Q3 2022.
  • 75 funds tracked by Wall St. Rank held Wave Life Sciences as of Q4 2022.

Based on Caxton Associates (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.